Evidence guide · US

VITAL's omega-3 results: fewer heart attacks, no reduction in the main heart outcome

VITAL gave 25,871 older adults fish oil or placebo for 5.3 years. Its main heart outcome, cancer and deaths were not reduced; heart attacks were about 28% lower as a secondary result. What the 2026 overview shows, atrial fibrillation risk and the dose used.

Review type: research summary. This page summarises published research and product labels, cited below.

VITAL is the large US trial that gave 25,871 older adults either a daily fish oil capsule or a placebo for a median of 5.3 years. On November 14, 2026 the VITAL research group published an overview of everything the trial's omega-3 arm and its ancillary studies have reported, in The Journal of Nutrition. The authors describe VITAL as the only large-scale randomized trial of marine omega-3 supplements for the primary prevention of cardiovascular disease and cancer in a general population not selected for raised risk.

Short answer: fish oil did not reduce VITAL's main heart outcome, a combination of heart attack, stroke and death from cardiovascular causes, and it did not reduce cancer or deaths from any cause. It was linked with fewer heart attacks, fewer fatal heart attacks, fewer artery-opening procedures and fewer recurrent heart-failure hospitalizations, but those were secondary results. The authors conclude that the findings do not support routine omega-3 supplementation among healthy adults for prevention of chronic disease, and that targeted supplementation of people with low fish intake and other select groups "warrants consideration".

What VITAL studied

VITAL enrolled US men aged 50 or over and women aged 55 or over who did not have cardiovascular disease or cancer, including 5,106 Black participants. It used a two-by-two design: participants were randomized to vitamin D3 (2,000 IU a day) or placebo, and separately to omega-3 or placebo. The omega-3 capsule was 1 g a day containing 840 mg of omega-3s: 460 mg of EPA and 380 mg of DHA. The two primary endpoints were major cardiovascular events and invasive cancer. The trial was funded by the US National Institutes of Health and others. Pharmavite (vitamin D) and Pronova BioPharma and BASF (Omacor fish oil) donated the study capsules, matching placebos and packaging.

The main result

  • Major cardiovascular events: 386 people in the omega-3 group and 419 in the placebo group, a hazard ratio of 0.92 (95% confidence interval 0.80 to 1.06). That is not statistically significant.
  • Invasive cancer: 820 v 797 people, hazard ratio 1.03. No reduction.
  • Death from any cause: hazard ratio 1.02 (978 deaths overall). No reduction.
  • Stroke and death from cardiovascular causes, taken separately, were not reduced either (hazard ratios 1.04 and 0.96).

Where fish oil did better

The 2026 overview lists these results for omega-3 compared with placebo. A hazard ratio below 1 means fewer events in the omega-3 group.

  • Total heart attacks: hazard ratio 0.72 (0.59 to 0.90), about 28% fewer.
  • Fatal heart attacks: 0.50 (0.26 to 0.97). The 2019 report counted 13 in the omega-3 group and 26 in the placebo group.
  • Percutaneous coronary intervention (stenting or balloon procedures to open heart arteries): 0.78 (0.63 to 0.95).
  • Recurrent heart-failure hospitalizations: 0.86 (0.74 to 0.998). In the VITAL-Heart Failure report, that secondary count was 326 events in the omega-3 group v 379 with placebo, counting every stay, including the first. First hospitalization for heart failure, that study's primary outcome, was not reduced (hazard ratio 0.96; 244 v 255).
  • Autoimmune disease: 0.82 (0.68 to 0.99) for confirmed plus probable cases, the same secondary result as in the 2022 BMJ report (208 v 249, P=0.04). In that report, confirmed cases alone were not statistically significant for omega-3 (130 v 148, hazard ratio 0.85, 0.67 to 1.08); vitamin D's confirmed-case result was 0.78 (0.61 to 0.99).

These are secondary or add-on results, and they need care. The original VITAL paper in the New England Journal of Medicine says there was no control for multiple hypothesis testing, so results for exploratory outcomes and subgroups "should be interpreted with caution". The heart failure authors say their exploratory analyses of recurrent hospitalization "require confirmation in future trials".

Who seemed to benefit more

The 2026 overview reports that demographic, dietary and clinical factors modified several results, with greater benefits in Black participants and in people with lower fish intake or cardiovascular risk factors, and variable effects in women compared with men. The 2019 paper also reported a suggestion of greater heart attack reductions in African American participants and in those with lower fish intake. These are subgroup findings from a trial whose main result was null. They point to who should be studied next; they do not show that a particular person will benefit.

Atrial fibrillation

Atrial fibrillation is an irregular heart rhythm. It is the safety outcome these fish-oil trials report. In VITAL Rhythm, which followed 25,119 participants, it occurred in 469 people (3.7%) on omega-3 and 431 (3.4%) on placebo, a hazard ratio of 1.09 (0.96 to 1.24) that was not statistically significant. A 2021 meta-analysis of seven cardiovascular trials (81,210 people), led by Gencer and co-authored by VITAL investigators Djousse, Cook, Manson and Albert, found omega-3 supplements were associated with a 25% higher risk of atrial fibrillation overall. The hazard ratio was 1.49 in trials using more than 1 g a day and 1.12 in trials using 1 g a day or less, and the risk rose by about 11% for each extra gram.

Side effects in VITAL

The 2019 paper reports no significant differences between omega-3 and placebo in gastrointestinal symptoms, major bleeding episodes or other serious side effects. The NIH Office of Dietary Supplements says side effects of omega-3 supplements are usually mild, such as an unpleasant taste in the mouth, bad breath, heartburn, nausea, stomach discomfort, diarrhea, headache and smelly sweat, and that high doses may cause bleeding problems when taken with warfarin or other anticoagulant medicines.

How VITAL fits with other trials

A 2020 Cochrane review of long-chain omega-3 trials found high-certainty evidence of little or no effect on deaths from any cause (risk ratio 0.97) and on cardiovascular events (0.96), and low-certainty evidence of a slight reduction in coronary heart disease events (0.91). VITAL's pattern, no overall cardiovascular benefit with a possible effect on heart attacks, sits within that picture.

Our view

  • For a healthy adult who already eats fish, VITAL is not a reason to start fish oil. Its main heart outcome, cancer and deaths from any cause were not reduced over a median of 5.3 years.
  • The heart attack hazard ratio, 0.72, is the same figure in the 2019 report and the 2026 overview, but it is a secondary endpoint from one trial. It is a signal, not proof.
  • People with low fish intake are one group the authors say warrants consideration, along with other select groups, including Black participants and people with cardiovascular risk factors in the 2026 overview. That is a subgroup finding. National advice on fish intake is below.
  • If you do take fish oil, VITAL's dose was 840 mg of EPA plus DHA a day. Check the EPA and DHA content on the label rather than the fish oil weight, and remember the atrial fibrillation risk in other trials was higher above 1 g a day.
  • VITAL enrolled people without cardiovascular disease, so these results are not a basis for using fish oil in place of prescribed heart medicines. The NIH says high doses of omega-3s may cause bleeding problems with warfarin or other anticoagulant medicines; speak to a doctor or pharmacist before starting fish oil if you take those medicines.

US guidance

The NIH Office of Dietary Supplements says recommended amounts of EPA and DHA have not been established. It reports that the American Heart Association recommends eating one to two servings of seafood a week to reduce the risk of some heart problems, especially if the seafood replaces less healthy foods; about 1 g a day of EPA plus DHA for people with heart disease, preferably from oily fish, with supplements an option under the guidance of a health care provider; and does not recommend omega-3 supplements for people who do not have a high risk of cardiovascular disease. The FDA recommends no more than 5 g a day of EPA and DHA combined from dietary supplements. FDA is not authorized to approve dietary supplements for safety and effectiveness before they are marketed, and advises consumers to talk with a doctor, pharmacist or other healthcare professional before deciding to purchase or use one.

FAQ

Does fish oil prevent heart attacks?

In VITAL, people taking fish oil had about 28% fewer heart attacks than those on placebo (hazard ratio 0.72; 145 versus 200 in the 2019 report). The primary heart outcome, heart attack, stroke or death from cardiovascular causes combined, was not significantly reduced. Heart attack was a secondary endpoint, and the 2019 paper says that with no control for multiple hypothesis testing, results for exploratory outcomes and subgroups "should be interpreted with caution".

What dose did VITAL use?

One 1 g capsule a day containing 840 mg of omega-3s: 460 mg of EPA and 380 mg of DHA, for a median of 5.3 years.

Should I take fish oil if I don't eat fish?

The VITAL authors say targeted supplementation of people with low fish intake and other select groups "warrants consideration", based on subgroup results. That is not a firm recommendation. They also say the findings do not support routine omega-3 supplementation among healthy adults for prevention of chronic disease. A doctor or pharmacist can advise on a supplement if you take other medicines.

Does fish oil cause atrial fibrillation?

In VITAL, at 840 mg a day of EPA plus DHA, the difference in atrial fibrillation was small and not statistically significant (3.7% v 3.4%). Across seven large trials, omega-3 supplements were linked with a 25% higher risk overall, and the risk was greater in trials using more than 1 g a day.

Sources

These are the documents this page relies on.

  1. Omega-3 Fatty Acid Supplementation Has Coronary and Other Selective Health Benefits: Comprehensive Results from the VITamin D and OmegA-3 TriaL (VITAL). J Nutr. 2026 (online November 14, 2026):101941The Journal of Nutrition (PubMed 43033966)
  2. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019;380(1):23-32New England Journal of Medicine (PubMed 30415637)
  3. VITAL omega-3 primary results: full text (methods, study capsule, subgroup and safety sections, funding)PubMed Central (PMC6392053)
  4. Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization: VITAL-Heart Failure. Circulation. 2020;141(9):784-786Circulation (PubMed 31709816; full text PMC7054158)
  5. Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial. JAMA. 2021;325(11):1061-1073JAMA (PubMed 33724323)
  6. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452BMJ (PubMed 35082139)
  7. Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation. 2021;144(25):1981-1990Circulation (PubMed 34612056)
  8. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3:CD003177Cochrane Library (PubMed 32114706)
  9. Omega-3 Fatty Acids: Fact Sheet for ConsumersNational Institutes of Health Office of Dietary Supplements
  10. Information for consumers on using dietary supplementsUS Food and Drug Administration